Volume 8, Supplement 7 (Dec 2017)
Volume 8, Supplement 7 (Dec 2017)
CLL is the most common leukemia in Western countries, with a population primarily over 70 years of age. Frailty and comorbidities are common concerns with established chemoimmunotherapy, but new FDA-approved therapies have led to specialized, specific treatments for the different stages of CLL.
Advertisement
Current Issue
Vol 17
No 6
Nov/Dec 2026
JADPRO Live 2026 APs at the Heart of Cancer Care
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, TCTCN, FAAN, FAPO
November 11, 2026
Enhancing Radiation Oncology Training for Advanced Practice Providers Through a Standardized Online Curriculum A Quality Improvement Initiative
Katherine Bukolt, DNP, APRN, FNP-C, AOCNP, ROCN, FAPO
November 11, 2026
Elevation Through Innovation An Updated Advanced Practice Provider Led Approach to Outpatient CAR T Cell Monitoring
Ashley E. Allington Drake, MSN, RN, AGACNP-BC, Virginia D. Quinn, MSN, RN, AGACNP-BC, Lauren A. Mason, MSN, RN, AGACNP-BC, Et al.
November 11, 2026